# THC And CBD From Marijuana Reduces Agitation In 9 Out Of 10 People With Alzheimer’s Or … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/thc-and-cbd-from-marijuana-reduces-agitation-in-9-out-of-10-people-with-alzheimers-or/ > **Published:** 2026-07-20T17:16:36-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:18:43-04:00 > **Clinical Summary:** Cannabinoids show promise for cannabis agitation dementia, but efficacy claims need clinical scrutiny. Evidence review and practical guidance. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchNeurologyTHCCBDAgingMental HealthSafety Why This Matters Clinicians treating Alzheimer’s disease and related dementias now have emerging evidence that [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) may effectively reduce agitation, a symptom that currently has limited pharmaceutical options and significantly impacts patient [quality of life](https://cedclinic.com/cannabis-policy-enforcement-february-26-2026/) and caregiver burden. This 2024 review provides a scientific foundation for clinicians to have informed discussions with patients and families about potential [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) as an adjunctive treatment while highlighting the need for further [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) to establish optimal dosing, safety profiles, and which patient populations benefit most. Given that behavioral symptoms like agitation often lead to unnecessary sedation or antipsychotics with serious adverse effects in older adults, [evidence-based cannabis](https://cedclinic.com/jama-cannabis-review-physician-analysis/) alternatives could reduce medication-related harms while improving neuropsychiatric Clinical Summary A 2024 systematic review found that THC, CBD, and other cannabis phytoconstituents demonstrate efficacy in reducing agitation across approximately 90 percent of patients with Alzheimer’s disease and related dementias, suggesting potential therapeutic benefit for behavioral symptoms that often drive caregiver burden and institutional placement. The review examined multiple cannabinoids and cannabis-derived compounds beyond THC and CBD, including lesser-studied phytocannabinoids, terpenes, and flavonoids, indicating that whole-plant cannabis effects may involve synergistic mechanisms rather than single-compound activity. For clinicians managing behavioral and psychological symptoms of dementia, these findings support consideration of cannabis-based interventions as an evidence-informed option when conventional pharmacotherapy fails or causes intolerable side effects, though the heterogeneity of study designs and dosing regimens limits definitive dosing recommendations. The high response rate reported warrants further controlled trials to establish optimal cannabinoid ratios, delivery methods, and patient selection criteria before cannabis becomes standard of care in dementia management. Clinicians should discuss cannabis as a potential off-label option with families of dementia patients experiencing significant agitation, while emphasizing the need for ongoing monitoring and the importance of source verification given regulatory variability in cannabis products. Dr. Caplan’s Take “The early signals here are worth watching, and I’ve seen behavioral improvement in some of my own patients with dementia-related agitation, but we need to be clear that a review synthesizing promising preliminary findings is not the same as robust clinical evidence—we still lack the large, controlled trials in human subjects that would let me recommend this with real confidence to my patients and their families.” Clinical Perspective 🧠 While preliminary evidence suggests cannabinoid compounds may reduce agitation in some patients with Alzheimer’s disease and related dementia, clinicians should approach these findings with appropriate caution given the limited number of rigorous controlled trials, heterogeneous patient populations, and variable cannabis formulations studied to date. The cited 9-in-10 response rate likely reflects selection bias and publication practices rather than generalizable efficacy, and important confounders such as concurrent medications, baseline cognitive status, and placebo effects remain inadequately controlled in much of the current literature. Additionally, cannabinoid use in older adults carries specific risks including altered cognition, falls, drug interactions, and regulatory uncertainty regarding product quality and standardization. For now, clinicians caring for patients with dementia-related agitation should continue to prioritize nonpharmacologic interventions and evidence-based treatments while remaining open to cannabinoids as a potential adjunctive option in carefully 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20THC%20And%20CBD%20From%20Marijuana%20Reduces%20Agitation%20In%209%20Out%20Of%2010%20People%20With%20Alzheimer%27s%20Or%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D70872)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D70872)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20THC%20And%20CBD%20From%20Marijuana%20Reduces%20Agitation%20In%209%20Out%20Of%2010%20People%20With%20Alzheimer%27s%20Or%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D70872)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [First-of-its-kind trial finds dementia agitation eased by cannabis combination](https://cedclinic.com/first-of-its-kind-trial-finds-dementia-agitation-eased-by-cannabis-combination/) - [Daily Digest: Cannabis Adolescent Psychiatric Risk Data Study](https://cedclinic.com/cannabis-adolescent-psychiatric-risk-data-study/) 📰 Source: [https://www.marijuanamoment.net/thc-and-cbd-from-marijuana-reduces-agitation-in-9-out-of-10-people-with-alzheimers-or-other-dementia-study-shows/](https://www.marijuanamoment.net/thc-and-cbd-from-marijuana-reduces-agitation-in-9-out-of-10-people-with-alzheimers-or-other-dementia-study-shows/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).